Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.

You may also be interested in...



Value-Based Pricing Could Boost Global Applicability Of NICE Appraisals

Value-based pricing will start in the U.K. in January 2014 for newly launched products, with prices taking into account innovation and societal benefit as well as NICE's usual clinical and cost-effectiveness analysis, U.K. Health Secretary Andrew Lansley tells NICE's annual conference.

European Regulatory Round-Up: EMA And The UK Heed The Calls Of Industry; France Is Otherwise Occupied

The European Medicines Agency follows through on its transparency initiative with comprehensive list of products under review and also reduces pharmacovigilence data reporting requirements.

EU Transparency Directive Revisions May Accelerate Access To New Medicines, But IP Issues Set To Cause A Storm

Proposed revisions to the EU Transparency Directive could drive faster access to medicines. But innovative product sponsors say IP rules will damage their business.

Related Content

Topics

UsernamePublicRestriction

Register

PS073826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel